Skip to main content
Theradiag logo

Theradiag — Investor Relations & Filings

Ticker · ALTER ISIN · FR00140069U4 LEI · 969500CDG241WHIFL611 PA Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2020-09-23 Report Publication Anno…
Country FR France
Listing PA ALTER

About Theradiag

https://www.theradiag.com/en/home-2/

Theradiag is a company that develops, manufactures, and markets in-vitro diagnostic (IVD) solutions, with a primary focus on theranostics. The company specializes in creating tools for monitoring biotherapies, which are treatments using substances derived from living organisms. Its core product line, Lisa-Tracker, is a range of kits designed to help clinicians measure the efficacy of biotherapies, particularly for patients with autoimmune diseases. This allows for the personalization of treatment and improved patient outcomes. In addition to its focus on biotherapy monitoring, Theradiag also maintains its activities in developing and distributing diagnostic tests for autoimmunity and oncogenetics. The company leverages its extensive experience to provide innovative diagnostic tools for clinicians and patients.

Recent filings

Filing Released Lang Actions
Rapports financiers et d'audit semestriels/examens réduits / Modalités de mise à disposition du rapport financier semestriel
Report Publication Announcement Classification · 100% confidence The document is a short announcement (2577 characters) titled 'Mise à disposition du Rapport financier semestriel 2020' (Availability of the 2020 half-year financial report). It informs the public that the report has been filed with the AMF and provides links to where it can be accessed. Per the 'Menu vs Meal' rule, this is an announcement of a report, not the report itself, and therefore falls under the Report Publication Announcement (RPA) category. H1 2020
2020-09-23 French
Half yearly financial reports and audit reports/limited reviews / Terms of availability of the half-yearly financial report
Report Publication Announcement Classification · 98% confidence The document explicitly states: '2020 Half-year financial report publication' and 'THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, today announces that its half-year financial report as at 30 June 2020 has been made available to the public and filed with the French regulator Autorité des Marchés Financiers (AMF).' This indicates an announcement about the release of a periodic financial report (half-year report). Since the document itself is short (2363 chars) and serves primarily to announce the availability of the full report, it fits the definition of a Report Publication Announcement (RPA) rather than the comprehensive Interim/Quarterly Report (IR) itself. The key phrase is 'announces that its half-year financial report... has been made available'.
2020-09-23 English
Informations privilégiées / Communiqué sur comptes, résultats
Interim / Quarterly Report Classification · 95% confidence The document is a comprehensive report detailing Theradiag's financial results for the first half of 2020 (S1 2020). It includes a detailed financial table (income statement), management commentary on business performance, operational highlights, and future outlook. While it mentions a conference call, the document itself contains the substantive financial data and analysis required for an interim report, distinguishing it from a mere announcement or press release. H1 2020
2020-09-21 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release from Theradiag announcing the market launch of a new COVID-19 antigen test. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general corporate announcement regarding business operations and product launches, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate news.
2020-09-21 English
Inside Information / News release on accounts, results
Earnings Release Classification · 100% confidence The document explicitly presents the "results for the six months ended June 30, 2020," including a detailed financial table comparing H1 2020 to H1 2019, management commentary on these results, and an outlook. This structure is characteristic of a comprehensive financial report covering a period shorter than a full year. The term 'H1 2020 results' strongly points towards an Interim/Quarterly Report. It is not an Earnings Release (ER) because it contains detailed financial tables and extensive commentary, suggesting it is more comprehensive than just key highlights. It is also not a full Annual Report (10-K) as it covers only six months. Therefore, the most appropriate classification is Interim / Quarterly Report (IR). H1 2020
2020-09-21 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is a press release from Theradiag dated September 21, 2020, announcing the commercialization of a new COVID-19 antigen test in France. It details the product, its regulatory context (mentioning the Journal Officiel), and provides company background. This type of announcement, focusing on a specific business event (product launch/commercialization) rather than periodic financial results (ER, IR, 10-K) or management changes (MANG), is best classified as a general Regulatory Filing or Announcement, as it pertains to market activity and regulatory compliance. Since there is no specific category for 'Product Launch Announcement' and it is not a standard financial report, the most appropriate fallback is 'Regulatory Filings' (RNS), as it is an official communication to the market regarding a significant operational/product development.
2020-09-21 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.